Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Total Non-Current Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 29.68% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 29.68% YoY) and the FY2025 annual result came in at $1.6 billion, up 27.53% from the prior year.
• Total Non-Current Liabilities eased to $1.5 billion in Q1 2026 per RARE's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.6 billion in Q4 2025 and bottomed at $301.3 million in Q2 2023.
• The 5-year median for Total Non-Current Liabilities is $1.1 billion (2025), against an average of $852.6 million.
• Peak annual rise in Total Non-Current Liabilities reached 288.61% in 2024, while the deepest fall reached 72.43% in 2024.
• Tracing RARE's Total Non-Current Liabilities over 5 years: stood at $317.5 million in 2022, then advanced by 11.26% to $353.3 million in 2023, then surged by 246.47% to $1.2 billion in 2024, then increased by 27.53% to $1.6 billion in 2025, then decreased by 5.0% to $1.5 billion in 2026.
• Per Business Quant, the three latest RARE Total Non-Current Liabilities figures stand at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $410.6 million (Q3 2025).

Peer Comparison